BR112018012260A2 - composição para hemostasia e método para hemostasia usando a composição para hemostasia - Google Patents

composição para hemostasia e método para hemostasia usando a composição para hemostasia

Info

Publication number
BR112018012260A2
BR112018012260A2 BR112018012260-2A BR112018012260A BR112018012260A2 BR 112018012260 A2 BR112018012260 A2 BR 112018012260A2 BR 112018012260 A BR112018012260 A BR 112018012260A BR 112018012260 A2 BR112018012260 A2 BR 112018012260A2
Authority
BR
Brazil
Prior art keywords
composition
hemostasis
self
assembling peptide
spray
Prior art date
Application number
BR112018012260-2A
Other languages
English (en)
Japanese (ja)
Inventor
Nagano Keiji
Kobayashi Satoru
Original Assignee
3-D Matrix, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3-D Matrix, Ltd. filed Critical 3-D Matrix, Ltd.
Publication of BR112018012260A2 publication Critical patent/BR112018012260A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0076—Sprayable compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/04—Materials for stopping bleeding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)

Abstract

[problema a ser resolvido] pretende-se proporcionar uma composição para hemostasia que possa ser uniformemente aplicada a um local de hemorragia e exerça um efeito hemostático elevado. [solução] a presente invenção proporciona uma composição a ser aplicada como uma pulverizador a um indivíduo, sendo o pulverizador utilizado para hemostasia, e a composição compreendendo um peptídeo de auto-montagem, em que o peptídeo de auto-montagem se auto-monta e, assim, forma gel quando a composição é aplicada a um local de hemorragia do indivíduo, e o peptídeo de auto-montagem está contido na composição em uma concentração em que a composição tem uma capacidade hemostática melhorada em comparação com aquela quando diretamente aplicada.
BR112018012260-2A 2015-12-18 2016-12-14 composição para hemostasia e método para hemostasia usando a composição para hemostasia BR112018012260A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015-247334 2015-12-18
JP2015247334 2015-12-18
PCT/JP2016/087298 WO2017104723A1 (ja) 2015-12-18 2016-12-14 止血用組成物、および、止血用組成物を用いた止血方法

Publications (1)

Publication Number Publication Date
BR112018012260A2 true BR112018012260A2 (pt) 2018-12-04

Family

ID=59056831

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018012260-2A BR112018012260A2 (pt) 2015-12-18 2016-12-14 composição para hemostasia e método para hemostasia usando a composição para hemostasia

Country Status (11)

Country Link
US (2) US11298397B2 (pt)
EP (1) EP3391897B1 (pt)
JP (1) JP6951252B2 (pt)
KR (1) KR20180102583A (pt)
CN (1) CN108697755A (pt)
AU (1) AU2016374425B2 (pt)
BR (1) BR112018012260A2 (pt)
CA (1) CA3008589C (pt)
ES (1) ES2896726T3 (pt)
HK (2) HK1258371A1 (pt)
WO (1) WO2017104723A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112368295A (zh) 2018-07-03 2021-02-12 立美基股份有限公司 离子性自组装肽
US20210220429A1 (en) * 2018-10-05 2021-07-22 Kurume University Pharmaceutical composition for treating or preventing ulcer or fistula in intestinal tract
WO2021146291A1 (en) * 2020-01-13 2021-07-22 Arch Biosurgery, Inc. Self-assembling peptide gel formulation and methods of use
CN112023113B (zh) * 2020-08-29 2021-11-30 田卫群 一种HNTs/RG5纳米复合止血粉的制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4049671A1 (en) 2004-07-06 2022-08-31 3D Matrix, Inc. Purified amphiphilic peptide compositions and uses thereof
EP1879606B1 (en) * 2005-04-25 2013-06-12 Massachusetts Institute of Technology Self-assembling peptides for promoting hemostasis
WO2008113030A2 (en) * 2007-03-14 2008-09-18 Arch Therapeutics, Inc Treatment of leaky or damaged tight junctions and enhancing extracellular matrix
BRPI0920030B1 (pt) * 2008-10-06 2019-03-26 3-D Matrix, Ltd. Agente de oclusão do tecido, agentes hemostáticos, preventivos e de oclusão ou escleroterapia relacionados, e infusão do tecido mucosal
JP2015142720A (ja) * 2013-12-27 2015-08-06 株式会社メニコン 止血材
CN106456811B (zh) 2014-03-10 2021-04-02 三维矩阵有限责任公司 肽组合物的灭菌和过滤
TWI537022B (zh) 2015-04-28 2016-06-11 國立清華大學 閉迴路腦電刺激裝置及其刺激電壓的產生方法

Also Published As

Publication number Publication date
JP6951252B2 (ja) 2021-10-20
EP3391897A1 (en) 2018-10-24
ES2896726T3 (es) 2022-02-25
US20220265757A1 (en) 2022-08-25
US11298397B2 (en) 2022-04-12
WO2017104723A1 (ja) 2017-06-22
AU2016374425A1 (en) 2018-06-21
EP3391897A4 (en) 2019-08-14
HK1258374A1 (zh) 2019-11-08
CA3008589C (en) 2024-01-23
CA3008589A1 (en) 2017-06-22
US20180360904A1 (en) 2018-12-20
KR20180102583A (ko) 2018-09-17
HK1258371A1 (zh) 2019-11-08
EP3391897B1 (en) 2021-09-08
CN108697755A (zh) 2018-10-23
JPWO2017104723A1 (ja) 2018-10-04
AU2016374425B2 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
CL2019001878A1 (es) Compuestos de microarn y métodos de modulación de la actividad de mir-21 (divisional solicitud 201402844).
BR112018012260A2 (pt) composição para hemostasia e método para hemostasia usando a composição para hemostasia
BR112015013464A2 (pt) curativo indicador de ph
BR112015022444A2 (pt) curativo de feridas vedante e uso do mesmo
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
BR112015016082A2 (pt) curativo indicador de umidade
AR088531A1 (es) Composiciones hemostaticas
ES2722923T3 (es) Procedimiento para preparar una emulsión de partículas de azufre elemental
CO6571868A2 (es) Procedimiento para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico
BR112016023851A2 (pt) ?composição de revestimento de duas partes e método para revestir uma superfície?
CR20160332A (es) Piridopirazolopirimidonas e indazolopirimidonas como inhibidores de fibrinólisis
BR112018074718A2 (pt) composição líquida não oleosa, não aquosa, e, método de controle de nematódeos.
PH12017501003B1 (en) Aminoacid-based composition for fibroelastin recovery in dermal connective tissues
MX366410B (es) Composiciones y metodos para tratamiento y reparacion de tendones.
BR112016015701A2 (pt) Dendrímero de peptídeo, método de esterilização do mesmo, composição, composição farmacêutica, método de polimerização de fibrinogênio, kit para formação de um hidrogel e hidrogel
BR112016002498A2 (pt) método para reduzir o teor de ácidos hexenurônicos em uma polpa celulósica química e/ou melhorar o brilho de polpa celulósica química, composição aquosa, e, utilização de uma haloperoxidase
BR112017023112A2 (pt) composição de curativo de ferida, método de fabricação da mesma, curativo de ferida, e, uso de uma composição de curativo de ferida
NZ710602A (en) Methods for reducing pyrogenicity in a seaweed extract
EA201591996A1 (ru) Способы и композиции для заживления раны
HK1260897A1 (zh) 使用四氫異喹啉小分子來結合並調節pcsk9的蛋白活性的組合物和方法
EA201592073A1 (ru) Фармацевтические композиции, содержащие коллаген и гиалуронат натрия
BR112014026483A2 (pt) composição antimicrobiana, composição antimicrobiana bicomponente, pano de limpeza, método para desinfetar uma superfície e método para controlar esporos sobre uma superfície
MX2019005693A (es) Factor viii direccionado a los globulos rojos y metodo para su uso.
EA201792085A1 (ru) Смешанные дисульфидные конъюгаты тиенопиридиновых соединений и их применение
EA201591389A1 (ru) Косметические композиции с трициклодеканамидами

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]